Allergy Therapeutics plc has been mentioned in a Form 8.5 (EPT/RI) disclosure by Panmure Gordon (UK) Limited. The disclosure states that Panmure Gordon (UK) Limited, as an exempt principal trader, has made purchases and sales of Allergy Therapeutics' 0.1p ordinary shares. The disclosure shows that Panmure Gordon (UK) Limited purchased 400,000 shares at a price of 0.027 per unit and sold 368,011 shares at a price of 0.02849 per unit. No cash-settled derivative transactions or stock-settled derivative transactions were reported. The disclosure also states that there are no indemnity or option arrangements, agreements, or understandings related to relevant securities. The contact person for the disclosure is Freddie Wooding, and the date of disclosure is September 7, 2023.

No other information or news about Allergy Therapeutics plc is provided in this disclosure.